# Send a correction to the watch desk

> Contact FDA Peptide Watch — Research Peptide Fundamentals — Contact the FDA Peptide Watch editorial desk about Research Peptide Fundamentals citations, status updates, corrections, or study coverage.

**EDITORIAL DESK / CORRECTIONS**

The most useful notes identify the page, the exact claim, and the source that changes the record.

## Editorial correspondence

FDA Peptide Watch welcomes evidence-based corrections and updates concerning semaglutide, tirzepatide, tesamorelin, and bremelanotide. Useful messages flag a citation mismatch, a changed regulatory status, a newly published peer-reviewed study, or wording that extends beyond the population actually studied.

A clear note includes the page path, the sentence at issue, and a source identifier or full bibliographic citation. That structure allows the desk to compare the proposed correction with the existing reference ledger and revise the claim without widening it beyond the evidence.

**Editorial mailbox:** editors@fdapeptide.com

## Scope of replies

The mailbox is for the publication record. It cannot evaluate symptoms, recommend a peptide, translate trial exposure into personal instructions, identify sellers, or assess whether an approved indication fits an individual case. Those questions require a licensed clinician working within the relevant jurisdiction and with access to the full clinical context.

Commercial placement, product-review, and sourcing requests are outside the desk’s remit. Messages about study design, citation integrity, regulatory wording, accessibility, or factual corrections receive editorial priority. A submission may be incorporated after source review, though individual replies and publication timelines are not guaranteed.

Regulatory notes benefit from exact language. A message about approval should identify the agency action, product, indication, population, and date represented in the supporting source. A message about a study should identify its design, comparator, enrolled population, endpoint, and publication. This detail helps the desk distinguish a true status change from a new experiment, an off-label discussion, or a claim that remains outside agency review. It also makes corrections faster to verify and easier to state without ambiguity.

---

FDA Peptide Watch is an independent status-and-evidence digest that keeps each peptide claim inside its reviewed indication and cited study record.